Please use this identifier to cite or link to this item: https://hdl.handle.net/1/270
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeung, D.en
dc.contributor.authorOsborn, M.en
dc.contributor.authorWhite, D.en
dc.contributor.authorBranford, S.en
dc.contributor.authorBraley, J.en
dc.contributor.authorHerschtal, A.en
dc.contributor.authorKornhauser, M.en
dc.contributor.authorIssa, S.en
dc.contributor.authorHiwase, D.en
dc.contributor.authorHertzberg, M.en
dc.contributor.authorSchwarer, A.en
dc.contributor.authorFilshie, R.en
dc.contributor.authorArthur, C.en
dc.contributor.authorKwan, Y.L.en
dc.contributor.authorTrotman, J.en
dc.contributor.authorForsyth, Cecily Jen
dc.contributor.authorTaper, J.en
dc.contributor.authorRoss, D.M.en
dc.contributor.authorBeresford, J.en
dc.contributor.authorTam, C.en
dc.contributor.authorMills, A.K.en
dc.contributor.authorGrigg, A.en
dc.contributor.authorHughes, T.en
dc.date.accessioned2015-05-04T23:42:14Zen
dc.date.available2015-05-04T23:42:14Zen
dc.date.issued2015-02en
dc.identifier.citationVolume 125, Issue 6, pp. 915 - 923en
dc.identifier.issn1528-0020en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/270en
dc.description.abstractThe Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL, imatinib 800 mg/day was given. Patients were then assessed against molecular targets: BCR-ABL1 </=10%, </=1%, and </=0.1% at 3, 6, and 12 months, respectively. Cohort 1 patients failing any target escalated to imatinib 800 mg/day, and subsequently switched to nilotinib 400 mg twice daily for failing the same target 3 months later. Cohort 2 patients failing any target switched to nilotinib directly, as did patients with intolerance or loss of response in either cohort. At 2 years, 55% of patients remained on imatinib, and 30% on nilotinib. Only 12% were >10% BCR-ABL1 at 3 months. Confirmed major molecular response was achieved in 64% at 12 months and 73% at 24 months. MR4.5 (BCR-ABL1 </=0.0032%) at 24 months was 34%. Overall survival was 96% and transformation-free survival was 95% at 3 years. This trial supports the feasibility and efficacy of an imatinib-based approach with selective, early switching to nilotinib. This trial was registered at www.anzctr.org.au as #12607000325404.en
dc.subjectCanceren
dc.subjectDrug Therapyen
dc.subjectHaematologyen
dc.subjectHematologyen
dc.subjectLeukemiaen
dc.subjectLeukaemiaen
dc.titleTIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.en
dc.typeJournal Articleen
dc.identifier.doi10.1182/blood-2014-07-590315en
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/25519749en
dc.identifier.journaltitleBlooden
dc.type.studyortrialClinical Trialen
dc.originaltypeTexten
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
crisitem.author.deptHaematology-
Appears in Collections:Haematology
Show simple item record

Page view(s)

20
checked on Mar 27, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.